Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -103.31% is 39% below its 5-year average of -74.52%, around the middle of its 5-year range (-227.96%–-32.28%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.15% above its 12-month average of -118.96%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -103.31%.
RETURN ON EQUITY (ROE)
-103.31%
RETURN ON EQUITY (ROE) AVG TTM
-118.96%
RETURN ON EQUITY (ROE) AVG 3Y
-75.49%
RETURN ON EQUITY (ROE) AVG 5Y
-74.52%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+13.15%
CURRENT VS 3Y AVG
-36.86%
CURRENT VS 5Y AVG
-38.64%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 745 covered companies
CURRENT VS SECTOR MEDIAN
-145.92%
vs the sector median at left
Korro Bio, Inc.
Market Cap
$96.65M
Return on Equity (ROE)
-103.31%
TTM Avg
-118.96%
3Y Avg
-75.49%
5Y Avg
-74.52%
Market Cap
$97.28M
Return on Equity (ROE)
-461.14%
TTM Avg
-233.39%
3Y Avg
-227.67%
5Y Avg
-163.94%
Market Cap
$99.01M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$99.23M
Return on Equity (ROE)
-584.65%
TTM Avg
-344.54%
3Y Avg
-57.14%
5Y Avg
-65.05%
Market Cap
$92.33M
Return on Equity (ROE)
-11.85%
TTM Avg
-51.56%
3Y Avg
-105.39%
5Y Avg
-105.39%
Market Cap
$91.46M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$90.32M
Return on Equity (ROE)
48.20%
TTM Avg
-54.60%
3Y Avg
-54.70%
5Y Avg
-44.17%
Market Cap
$102.64M
Return on Equity (ROE)
23.96%
TTM Avg
-4.38%
3Y Avg
-11.56%
5Y Avg
6.84%
Market Cap
$90.41M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korro Bio, Inc. (KRRO) | $96.65M | -103.31% | -118.96% | -75.49% | -74.52% |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.28M | -461.14% | -233.39% | -227.67% | -163.94% |
| Conexeu Sciences Inc. (CNXU)vs › | $99.01M | N/A | N/A | N/A | N/A |
| PolyPid Ltd. (PYPD)vs › | $99.23M | -584.65% | -344.54% | -57.14% | -65.05% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $92.33M | -11.85% | -51.56% | -105.39% | -105.39% |
| Biomea Fusion, Inc. (BMEA)vs › | $91.46M | -268.09% | -238.76% | -155.55% | -124.74% |
| Rallybio Corporation (RLYB)vs › | $90.32M | 48.20% | -54.60% | -54.70% | -44.17% |
| The Joint Corp. (JYNT)vs › | $102.64M | 23.96% | -4.38% | -11.56% | 6.84% |
| Equillium, Inc. (EQ)vs › | $90.41M | -32.15% | -60.32% | -93.79% | -79.41% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $103.06M | -34.11% | -78.33% | -16.94% | -8.09% |
ROE
-103.3%
ROA
-65.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -103.31% |
| 2026-03-31 | -94.87% |
| 2025-12-31 | -227.96% |
| 2025-09-30 | -89.28% |
| 2025-06-30 | -79.37% |
| 2025-03-31 | -62.91% |
| 2024-12-31 | -52.10% |
| 2024-09-30 | -48.88% |
| 2024-06-30 | -43.06% |
| 2024-03-31 | -53.60% |
| 2023-12-31 | -47.77% |
| 2023-09-30 | -130.38% |
| 2023-06-30 | -100.33% |
| 2023-03-31 | -85.41% |
| 2022-09-30 | -104.57% |
| 2022-06-30 | -95.28% |
| 2022-03-31 | -77.84% |
| 2021-12-31 | -64.73% |
| 2021-09-30 | -49.90% |
| 2021-06-30 | -32.28% |
| 2021-03-31 | -23.66% |
| 2020-12-31 | -13.77% |
| 2020-09-30 | -10.91% |
| 2020-06-30 | -10.52% |
